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THe CounTry ArCHeTyPe Model: unloCking THe door To globAl 
MArkeT ACCess
Moore R.1, Cox J.2
1Decision Resources Group, Nashville, TN, USA, 2Decision Resources Group, London, UK
Financial constraints versus public desire for more-generous healthcare create a 
difficult dilemma for countries globally. As each market strives to manage its pre-
scription drug market, highly specific market access requirements and challenges 
abound for drugmakers. Innovative developers must engage with payers much 
earlier in the product development cycle in order to optimize trial design to satisfy 
specific MA and payer requirements on demonstrating innovation (e.g. selecting 
the appropriate comparator, targeting the correct/local patient population, gather-
ing the most compelling head-to-head). By exploring how pricing and reimburse-
ment (P&R) decisions are made in many major and developing markets around the 
world, we have developed a Country Archetypes model that identifies similarities 
among payer requirements, and, vitally, determines where product value messaging 
can be leveraged to optimize market access strategy. Data on payer type and drug 
review processes, payer fragmentation, percentage of individuals covered by a health 
insurance system, size of the pharmaceutical market, percentage of government 
and individuals in healthcare spending, and use as a reference country for other 
nations were collected for 27 of the largest pharmaceutical markets in the world. 
Considerations around free pricing, health technology assessment, and review of 
pharmacoeconomic and outcomes research data rules were made, and further seg-
mentations on decision impact, size of reimbursable market, out-of-pocket costs, 
role of health insurance and market fragmentation applied. Ultimately, from the 
27 nations examined, six groups emerged, each comprising countries with com-
monalities across all measures, albeit distinct profiles that affect P&R: Accountants, 
Pragmatists, Evidence seekers, Deal-makers, Ceiling setters, and Independents. 
Our Country Archetype model is intended to help multinational pharmaceuti-
cal companies prepare for local reimbursement evaluations, and pinpoint where 
decision-makers can be found. With classifications based on the most important 
set of reimbursement criteria necessary to attain favorable access in each market, 
the keys to access can be found and turned.
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A siTuATion AnAlysis of HeAlTH PoliCy And HeAlTH TeCHnology 
AssessMenT in kAzAkHsTAn
Kostyuk A.1, Akanov A.2, Karp L.2, Nurgozhin T.3, Almadiyeva A.2
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Kazakhstan is an upper-middle-income country with per capita GDP of nearly US$13 
thousand in 2013. Kazakh’s public healthcare system – UNHS (Unified National Health 
System) – aims to deliver healthcare coverage to the whole population. Despite this 
objective, only two thirds of interventions (on average) in UNHS were fully covered by 
public funding, while the remaining were funded by patients through either private 
health schemes or out-of pocket payments. Finding better ways to manage the use 
and cost of health technology is a high priority for Kazakh policy makers. As health 
policy makers face increasing pressure from the public to make explicit determina-
tions about how and which technologies will be covered within the state guaranteed 
benefits package, the profile and scrutiny of HTA activity has, consequently, also 
increased. Even though there has been a rapid growth of HTA activities, HTA has not 
been developed as much as expected. There are several possible reasons why the MoH 
did not develop the strategy adopting HTA. First, comprehensive evaluation through 
HTA would make clear the failure of health policy previously implemented. Second, 
the MoH still relied on the traditional consensus method based on opinion or experi-
ence, which favors incremental and marginal changes, rather than a drastic reform. 
Third, there has been a power game of politics between innovative and conservative 
groups in the MoH. The Kazakh health care system needs HTA to be constructive to 
enable decision makers to make informed decisions with regard to the adoption of 
health technology. The development and promotion of clear criteria for selection of 
HTA topics is, therefore, essential to promote the efficient use of HTA information for 
decision making with respect to setting ultimate goals for HTA.
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THe eMerging role of PATienT-rePorTed ouTCoMes (Pros) in CliniCAl 
TriAls in indiA
BN V.1, Naidu M.2, Esam H.2, Badgujar L.2, Kinra G.2, Dang A.2
1Velammal Medical College Hospital and Research Institute, Madurai, India, 2MarksMan 
Healthcare Solutions LLP (HEOR and RWE Consulting), Navi Mumbai, India
Despite the average Indian patient becoming more knowledgeable with regards to 
his/her health, disease and treatment options, many Indian physicians still depend 
heavily on disease-related outcome measures to take health-care related decisions, 
and give minimal importance to patient-reported outcomes (PROs) pertaining to the 
effect of the healthcare interventions on the patient’s well-being. This trend is also 
seen in clinical trials (CTs) in India where PROs, if used, are only secondary to disease-
related outcomes. As on today, there are no commendable patient-centered outcome 
researches (PCORs) happening in India. With the arrival of PCOR Institute (PCORI) in 
the US, PROs are now getting the attention that they deserve; however, in India the 
concept is yet to catch up. PROs have a significant role in CTs, such as determination 
of patient eligibility, determination of patient compliance, as a study endpoint, deter-
mination of health-related quality of life (HRQoL), and assessing economic burden and 
indirect impact of disease and treatment. Implementation of regular PROs assessment 
in clinical trials can help in determining the negative effects of therapy, comparing 
two standard therapies having similar survival outcomes, finding out whether a new 
therapy is preferable to standard therapy, determining whether a therapeutic regimen 
is better than supportive care only, when survival time is short, and making the com-
munication easier in clinical practice. Improved design and proper implementation 
of PROs in clinical trials (CTs) are necessary to provide high quality evidence to syn-
thesize clinical practice guidelines. Implementation of PROs in CTs should be made 
mandatory for pharmaceutical companies to prove their label claims, especially in 
a country like India where the generic market is strong and widespread. Also, data 
obtained from PROs in CTs should be made the source document for making health-
related decisions at all levels in India.
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THe PillArs of CosT-effeCTiveness: A PrACTiCAl guideline for new 
TeCHnology CosT-effeCTive deCision-MAking
CalderÓn M.R.
Novartis Pharmaceuticals, Guatemala, Guatemala
BACKGROUND: The critical importance and use of health technology assessment 
in health care decisions towards improved health is practically nonexistent in 
many Central American and Caribbean countries. A culture with a health eco-
nomics mindset that enhances access to new technologies is needed, one that 
increases the knowledge and application of economic evaluation amongst health 
stakeholders to make cost-effective decisions that improve health. OBjeCtives: In 
general, to find new ways to make new drugs and technologies available to patients, 
healthcare providers, governments and society as a whole. Specifically, to develop 
a practical guideline for the pharmaceutical and healthcare industries to make 
new technologies available to patients in resource-limited settings. MethODs: A 
needs assessment was conducted amongst key internal (pharmaceutical industry) 
and external stakeholders (public, private and non-profit institutions) in Central 
America and the Caribbean to gain insight into their decision-making basis and 
behaviors regarding new technology acquisition. A literature review of lessons 
learned and best practices around the world complemented the information col-
lected from local stakeholders. ResUlts: A pivotal concept was created and coined 
as Pillars of Cost-Effectiveness. This concept advocates for three types of “effective-
ness” comprising each three types of strategic considerations as follows: 1. Clinical 
Effectiveness: safety, efficacy and quality, 2. Medical Access Effectiveness: value-
added services, impact information dissemination and managed-entry agreements, 
and 3. Economic Effectiveness: burden of disease data, cost-effectiveness evidence 
and budget impact analysis. CONClUsiON: The Pillars of Cost-Effectiveness may 
serve as the “New Technology Cost-Effectiveness Checklist” to make evidence-based 
decisions in resource-limited settings. In turn, it may become the tool to assess 
and assure the universal goals of patients, providers, payers and policy-makers to 
(1) get the best drug and technology quality at the lowest cost and with reasonable 
access, and (2) enhance healthcare partnerships and solutions towards improved 
individual and population health outcomes.
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BACKGROUND: Cancer is an increasing problem in developing countries. It ranks 
as the fourth leading cause of death in the eastern Mediterranean region and is 
one of the leading causes of death in the world. Although, in developing countries, 
incidence of cancer is still below that in the developed ones, they are expected to 
experience an increase in the burden of cancer, which if added to the more limited 
resources available, requires immediate intervention. Multiple projects had been 
initiated, but facing technical and other problems related to resources and equity 
leads them to be ineffective and inefficient. Objectives: Developing the nucleus for 
numerous Oncology Hospital-Based HTA (HB HTA) units as a tool for evidence based 
decision making and better utilization of resources to reach for a highly performing 
healthcare system. MethODs/RespONsiBilities: Decentralized HB HTA emerges 
from the need to take tailored healthcare decisions in a short period of time. These 
decisions should make use of local intrinsic data, providing solutions that are com-
patible with the hospital’s values and priorities. Generally, responsibilities include 
receiving requests (according to certain technical, medical, clinical, economic, and 
social aspects) from Healthcare Practitioners and/or decision makers in relation 
to the adoption of certain technology/intervention. This unit then aggregates all 
the available data (from primary and secondary sources), synchronize and analyze 
them appropriately, resulting in site-relevant clinical and economic final assess-
ments. DisCUssiON: A single university (department) experience as a nucleus for 
HB HTA is centered on the three main interest of a university hospital: Research, 
Education and Clinical practice. It depends on the presence of: 1- A chemotherapy 
independent unit which can provide standardized regimens based on the HTA-based 
decisions, 2- Well-developed oncology electronic medical record to insure standard-
ized data collection and rapid communication between different departments, 3- an 
E-learning program, and 4- a clinical research unit.
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AugMenTing THe regulATory requireMenTs of MediCATion THerAPy 
MAnAgeMenT To iMProve ProgrAM effiCienCy And ouTCoMes
Mbagwu G.1, Godley P.2
1The University of Texas at Austin, Austin, TX, USA, 2Scott & White Health Plan, Temple, TX, USA
The Medicare Modernization Act of 2003 requires prescription drug plans to pro-
vide medication therapy management services to eligible Part D beneficiaries. 
In 2010, in an attempt to increase consistency among programs, the Centers for 
Medicare and Medicaid Services (CMS) expanded the regulatory requirements 
associated with medication therapy management (MTM). After evaluating the 
outcomes of MTM since its implementation in 2006, CMS concluded that the pro-
gram has fallen short of expectations. On implementation of MTM, CMS projected 
that 25 percent of Medicare beneficiaries would qualify for MTM based on the 
proposed eligibility criteria. In reality, the percent of MTM eligible beneficiaries 
has fallen far below that approximation. Among members who meet eligibility 
criteria, MTM completion rates remain around 20 percent, on average. CMS also 
notes that certain racial and ethnic disparities continue to exist in MTM eligibil-
ity. Specifically, African American and Hispanic beneficiaries are less likely to 
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meet eligibility criteria when compared with their Caucasian counterparts. These 
identified shortcomings related to MTM delivery within the Part D population 
remain unresolved. In order to target beneficiaries that will benefit most from 
MTM services, and ensure optimal outcomes in all MTM delivery settings, our 
recommendations to CMS are as follows: CMS should incorporate medication 
adherence measures into annual MTM eligibility criteria; CMS should require 
that plan sponsors adhere to the industry standard of including at least 25% of 
their total Part D population in MTM programs; CMS should include MTM out-
comes data in the determination of health plan star ratings and reimburse-
ment structures; and CMS should require health plans and affiliated healthcare 
organizations to grant MTM providers access to patients’ electronic medical 
records.
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CoMMerCiAl HeAlTH insurAnCe – A new Power To PusH CHinA 
HeAlTHCAre reforM forwArd?
Ma R., Huang L., Zhao D., Xu L.
Astrazeneca (China), Beijing, China, Commercial health insurance – A new power to push China 
healthcare reform forward?
BACKGROUND: The coverage and payment level of China basic medical insurance 
grew rapidly during the healthcare reform. Those growth leads huge pressure to 
the financing mechanism. How to well allocate limited budget is a challenge. Thus 
the government started to buy commercial health insurance for some critical dis-
eases for people since 2012. In 2014, the State Council further published 2 notifica-
tions to encourage commercial insurance agencies to take more responsibility in 
healthcare. MethOD: This article searched and reviewed the studies for the medical 
insurance system of China, US (the country with the largest commercial insurance 
system) and UK (typical universal welfare country), then compared social environ-
ment (population, age structure and etc.), economic status, government structure 
and medical insurance system among the 3 countries, to discuss the possibility 
that commercial health insurance can solve the challenge in the reform. ResUlts 
AND DisCUssiON: Those factors compared are different and decide that commer-
cial health insurance will play different role. Although China government wish to 
provide universal basic medical insurance like UK, while the limited inputs pushed 
the government have to consider US mode. The policies from the State Council 
in 2014 encouraged commercial insurance agencies “comprehensive interfere in 
the management of medical insurance”, and “give more preference to commercial 
insurance”. However commercial health insurance is hard to relieve the financial 
pressure in the reform: 1. Currently commercial insurance agencies are only allowed 
to interfere in critical diseases and will face high risk (and potential loss); 2. The 
government only allow state-owned agencies to participate, hence government 
still needs to pay the bill for the potential loss; 3. Unlike US, all Chinese residents 
should participate basic medical insurance, and the financial pressure will continue 
to increase due to aging population.
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PATienT regisTries in indiA – nATionAl CAnCer regisTry ProgrAM
Janodia M., Udupa N.
Manipal University, Manipal, India
A patient registry is defined, by Gliklich and Dreyer, as “an organized system that 
uses observational study methods to collect uniform data (clinical and other) to 
evaluate specified outcomes for a population defined by a particular disease, con-
dition or exposure, and that serves one or more predetermined scientific, clinical, 
or policy purposes”. In a vast country like India it is important to have patient 
registries in order to understand epidemiology and plan healthcare programs 
effectively in order to reduce morbidity and mortality, and develop a long term 
strategy to provide appropriate care to patients. First such registry was started 
in India by Indian Council of Medical Research (ICMR) in December 1981, which 
was a network of cancer registries across the country. This program was termed 
National Cancer Registry Program (NCRP). The objectives of the NCRP were to 
generate reliable data on magnitude and patterns of cancer, undertake epide-
miological studies, provide strategies for National Cancer Control Program and 
Develop human resource in cancer registration and epidemiology. The data for 
NCRP is collected through hospital based cancer registry and population based 
cancer registry. The NCRP has generated invaluable human resources in cancer 
epidemiology and registration. The registry has provided high level data on cancer 
occurrence, which is used for National Cancer Control Program (NCCP). However, 
the notification of cancer cases by public and private hospitals, for NCRP, is not 
mandatory. This might lead to possibility of many cancer cases go unnoticed. A 
mechanism to have nodal agencies to collect and collate data from public and 
private hospitals as well as private nursing homes, through legislation mandating 
compulsory reporting of cancer cases might provide much more useful informa-
tion on epidemiology, morbidity and mortality cases along with future direction 
for designing intervention strategies.
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HeAlTH dATA enTAngleMenT And ArTifiCiAl inTelligenCe-bAsed 
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Healthcare spending has been keeping on rising faster than national gross domestic 
product. The public healthcare expenditure can be associated with two major key 
categories: demographic and economic drivers. The increase of healthcare budget 
in response to growing demand without its assessment and governance is no longer 
a valuable option. Health data are essential because their analyses give the chance 
to allow a better comprehension of health events experienced in patients’ real life. 
Moreover, it is worth noting that health data are also extremely important as a 
compelling tool in evaluation and advancement of health governance. In spite of its 
magnitude in the overall economy, the tangled key elements that drive healthcare 
expenditure have been rarely recognised, measured and comprehended. To tackle 
the healthcare spending growth, it may be useful to design and implement an effec-
tive, advanced system to generate and analyse real and qualified health data. To 
this purpose, the methodological approach given by the Health Data Entanglement 
is a particularly suitable option. Entanglement concept is borrowed from quantum 
physics and means that multiple particles (or information) are linked together in 
a way such that the measurement of one particle’s quantum state (in our context, 
individual health conditions and related economic requirements) determines the 
possible quantum states of other particles (i.e. population health forecasts to pre-
dict their overall impact and support policy decisions). The value created by the 
Health Data Entanglement is based on wider and combined evaluation of clinical, 
economic and social effects generated by health interventions. Subsequent analyses 
of data can be performed using the self-learning artificial intelligence, in which 
sequential decisions are based on Bayesian algorithmic probabilities. Health Data 
Entanglement and artificial intelligence-based analyses can be adopted to improve 
the effectiveness of health governance system in ways that also lead to better qual-
ity of care.
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PoPulATion bAsed vAluATion of PrivATe AnnuiTy And life insurAnCes 
under TAiwAn’s nATionAl HeAlTH insurAnCe sysTeM
Hsu W.W.1, Wu Y.1, Yu P.1, Hsieh H.1, Ho J.2
1National Taiwan Ocean University, Keelung, Taiwan, 2Academia Sinica, Taipei, Taiwan
OBjeCtives: National Health Insurance of Taiwan has offered every citizen equal 
access to health services and financial risk protection from medical expenses. In 
addition, purchasing private insurances is still popular. The average contracts owned 
per person is 2.23 in 2012 and has increased to 2.30 in 2013. The premium cost of 
the National Health Insurance of Taiwan is not a user charged policy, but rather 
an income-based formula, and most insurances including the National Health 
Insurance is powered by workforces from the younger cohort. We want to esti-
mate the value of insurance policies by adding the population structure factor. This 
will reveal the impact to the average value as the population changes. MethODs: 
We have added the population module into our FinancialCloud system. Data are 
acquired from Taiwan government open data and dynamic information, i.e., interest 
rate and foreign exchange rates, are update daily. By computing every possible out-
put of insurance policies for each age cohort (in 5-years interval, e.g. 0-4, 5-10, and 
so on), we can derive the expected value of a policy. A single year, single term policy 
pricing may require more than 50 thousand evaluations. For multiple years, terms, 
and policies, our FinancialCloud is especially suitable for massive, distributed, and 
parallel computations. ResUlts: Considering a single cohort over the total popu-
lation can cause price differences of more than 2%, and can even be greater if the 
term length and population structure changes. For 10 years term, approximately 60% 
younger cohort is supporting the 40% older cohort, and changes to 68%/32% in 20 
years estimate. CONClUsiONs: For different cohort, the value of a same insurance 
policy can be different. This factor must be considered to get a better estimate of the 
policy’s expected value. Rebalancing the premium fee for insurances is necessary if 
the population structure changes.
diseAse- sPeCifiC sTudies
individuAl’s HeAlTH – Clinical outcomes studies
PiH1
CoMPAring MediCAl THerAPies for HeAvy MensTruAl bleeding relATed 
To uTerine fibroids
Yao X1, Stewart EA1, Laughlin-Tommaso SK1, Borah BJ2, Heien HC1
1Mayo Clinic, Rochester, MN, USA, 2Mayo Clinic College of Medicine, Rochester, MN, USA
OBjeCtives: Uterine fibroids (UF) affect more than one-fifth of US reproductive age 
women. While multiple medical therapies are available, there are little data on how 
long patients stay on a medical therapy before they switch to other medications or 
procedural treatment. Identifying successful and lasting medical therapies would 
better inform patients and providers, and reduce the number of hysterectomies. This 
study compares four medication classes (short-acting reversible contraceptive ster-
oids (SARC), long-acting reversible contraceptive steroids (LARC), leuprolide acetate 
(LA) and tranexamic acid (TA) for controlling heavy menstrual bleeding (HMB) in UF 
patients. MethODs: Using a large private health insurance claims database (Optum 
Labs Data Warehouse), we identified women aged 18-54 with UF and HMB diagnoses 
and medical therapy between 2000 and 2013. We defined patients’ first medica-
tion after diagnosis as the index medication (and the study drug cohorts), and 
assessed the duration of their index medical therapy and whether they switched. 
Propensity score matching and survival analysis were used to compare different 
medications. ResUlts: Of the 41,561 eligible women, the four drug cohorts had 
33,000 (79.4%: SARC), 3,928 (9.5%: LARC), 3,525 (8.5%: LA), and 1,108 (2.7%: TA), respec-
tively. 16,594 (40.0%) switched to non-index medication or procedural treatment. 
Among the patients who switched, 45.7% switched to hysterectomy, 24.1% switched 
to endometrial ablation, 8.5% switched to myomectomy, and 18.4% switched to 
another medication class. Patients on LARC were much less likely to switch in the 
short term (e.g., within 60 days), but the effect was similar to SARC in the long term 
(on average HR= 0.63, p< 0.001). Patients on leuprolide acetate (HR= 2.41, p< 0.001) 
and tranexamic acid (HR= 1.49, p< 0.001) were more likely to switch, compared to 
those on SARC. CONClUsiONs: When treating HMB related to UF, women are more 
likely to stay on medications that have contraceptive benefits (i.e., LARC and SARC), 
compared to leuprolide acetate and tranexamic acid.
